QMSR for CROs: How the New Regulation Affects Testing and Consulting Services (Part 5)

Contract research organizations occupy a unique position in the medical device ecosystem. While CROs don't typically hold FDA establishment registrations as manufacturers, the quality of services they provide directly impacts their clients' QMSR compliance, biocompatibility evaluations, and regulatory submissions.

The QMSR's emphasis on process-based quality management, expanded FDA inspection authority, and integration of biocompatibility with design controls creates both challenges and opportunities for CROs providing testing, analytical, and consulting services to medical device manufacturers.

This is Part 5 of our QMSR series. If you haven't read Parts 1-4, review those for comprehensive understanding of QMSR requirements, inspection readiness, biocompatibility integration, and implementation strategies.

How the QMSR Affects CRO Operations

While CROs may not be directly subject to QMSR requirements in the same way manufacturers are, the regulation significantly impacts how CROs operate and what clients expect.

Quality System Expectations for CROs

ISO 17025 alignment becomes more critical. Many CROs operate under ISO/IEC 17025 for laboratory testing. With the QMSR incorporating ISO 13485:2016, manufacturers increasingly expect CRO quality systems to align with international standards and demonstrate systematic quality management.

Process-based thinking matters. The QMSR's emphasis on process-based quality management means manufacturers want CROs who understand how testing fits into broader device development processes, not just laboratories that execute protocols.

Documentation rigor increases. With FDA's expanded inspection authority under the QMSR, manufacturers need CRO reports that withstand regulatory scrutiny. Test reports must be complete, traceable, and clearly support regulatory conclusions.

Traceability requirements expand. Manufacturers operating under the QMSR need clear traceability from device description through test article preparation, testing execution, results, and interpretation. CRO documentation must support this traceability.

Supplier Management Under the QMSR

CROs are suppliers to medical device manufacturers, which means they're subject to their clients' supplier management requirements under the QMSR.

Expect supplier evaluations. Manufacturers must evaluate and monitor CRO capability to meet specified requirements. This may include:

• Quality system assessments or audits

• Review of accreditations, certifications, or registrations

• Evaluation of technical competency and equipment qualification

• Assessment of turnaround times and communication effectiveness

Performance monitoring will increase. The QMSR requires ongoing supplier performance monitoring. Manufacturers will track:

• Test report quality and completeness

• Adherence to protocols and timelines

• Responsiveness to questions or issues

• Accuracy and consistency of results

Supplier audit reports are now reviewable by FDA. Under the QMSR, FDA can review supplier audit reports during inspections. This means manufacturer audits of CROs may be examined by FDA investigators, raising the stakes for both parties.

Change notifications become critical. CROs must notify manufacturer clients of changes that could affect service quality—personnel changes, equipment changes, facility moves, accreditation status, or process modifications.

Biocompatibility Testing Services Under ISO 10993-1:2025

The shift to risk-based biological evaluation under ISO 10993-1:2025 fundamentally changes what manufacturers need from biocompatibility testing CROs.

From Routine Testing to Strategic Evaluation

Testing is no longer automatic. Under ISO 10993-1:2025, manufacturers must conduct biological risk assessment before determining what testing is needed. This means CROs can't assume clients will order the "standard battery" of tests based on device contact type.

Justification matters more than execution. Manufacturers need help understanding whether testing is necessary, not just executing tests. CROs who provide strategic guidance on when testing can be avoided through chemical characterization or existing data create more value than those who simply run protocols.

Chemical characterization integration increases. ISO 10993-1:2025 emphasizes using chemical characterization to address systemic biological endpoints before conducting animal testing. CROs offering integrated chemical and biological testing services are better positioned to support clients' risk-based evaluation strategies.

What Manufacturers Now Expect from Testing CROs

Test strategy consultation. Help determining which biological endpoints require testing versus which can be addressed through chemical characterization and toxicological risk assessment.

Protocol customization. Test protocols tailored to device-specific characteristics, clinical use scenarios, and regulatory strategy rather than generic approaches.

Scientifically defensible test articles. Clear documentation of how test articles were prepared to represent clinical use, including extraction conditions, sterilization, and handling that matches actual device configuration.

Interpretation support. Expert interpretation of results in context of device characteristics, clinical use, and regulatory expectations—not just pass/fail determinations.

Integration with chemical data. Ability to integrate biological test results with chemical characterization data for comprehensive biological evaluation reports.

Chemical Characterization Services Under the QMSR

Chemical characterization has become central to biological evaluation under ISO 10993-1:2025, creating expanded opportunities for CROs with analytical chemistry capabilities.

Extractables and Leachables Testing

Study design expertise matters. Manufacturers need CROs who can design extraction studies that appropriately simulate clinical use conditions, not just apply generic protocols. This requires understanding:

• Device contact characteristics and clinical use scenarios

• Appropriate extraction vehicles based on contact type

• Extraction parameters (temperature, duration, surface area ratios)

• Analytical methods suitable for expected constituents

Comprehensive analytical capabilities. Effective extractables studies require multiple analytical techniques (GC-MS, LC-MS, ICP-MS, IC, etc.) to identify and quantify diverse chemical constituents. Single-technique laboratories provide incomplete characterization.

Low detection limits and sensitivity. As toxicological risk assessment becomes more sophisticated, manufacturers need analytical methods with detection limits low enough to support meaningful safety conclusions.

Clear reporting of unknowns. Not all detected compounds can be identified. CRO reports must clearly distinguish identified compounds from unknowns and provide sufficient spectral data for toxicological assessment.

What Manufacturers Expect from Analytical CROs

Validated analytical methods. Clear documentation of method validation including specificity, linearity, accuracy, precision, detection limits, and quantitation limits.

Appropriate quality controls. Use of blanks, positive controls, and reference standards demonstrating analytical reliability.

Complete data packages. Raw data, chromatograms, spectra, and detailed analytical narratives supporting regulatory submissions—not just summary tables.

Regulatory-ready reports. Documentation organized for direct inclusion in regulatory submissions with clear methods, results, and analytical limitations.

Responsive technical support. Ability to answer FDA questions about analytical methods, detection capabilities, or specific findings during regulatory review.

Toxicological Risk Assessment Services

The QMSR's integration of biocompatibility with design controls and risk management creates significant opportunities for CROs offering toxicological expertise.

Why Toxicological Services Are Increasingly Valuable

Manufacturers lack internal expertise. Most medical device companies don't employ toxicologists, creating dependence on external experts for interpreting chemical characterization data and biological test results.

ISO 10993-1:2025 requires scientific justification. The risk-based biological evaluation framework demands clear scientific rationale for all testing decisions and safety conclusions. This requires toxicological expertise most manufacturers don't possess internally.

FDA expects toxicological risk assessment. Regulatory reviewers increasingly expect systematic toxicological evaluation of chemical constituents, not just analytical data or biological test results alone.

Integration challenges are complex. Connecting chemical characterization, biological testing, and risk management requires specialized knowledge spanning analytical chemistry, toxicology, and regulatory strategy.

Toxicological Services CROs Can Provide

Constituent identification and evaluation. Interpreting analytical chemistry results to identify chemical constituents and assess toxicological significance.

Exposure estimation. Calculating patient exposure based on constituent concentrations, device contact characteristics, and clinical use scenarios.

Hazard assessment. Identifying toxicological hazards associated with detected constituents using literature, databases, and structure-activity relationships.

Threshold comparison. Comparing estimated exposures to appropriate toxicological thresholds (TDI, PDE, TTC, NOAEL) with appropriate safety factors.

Margin of safety calculation. Determining whether margins between exposure and thresholds are adequate for the intended use and patient population.

Biological evaluation report preparation. Integrating chemical, toxicological, and biological data into comprehensive reports meeting ISO 10993-1:2025 and QMSR requirements.

Scientific justification documentation. Preparing clear rationales for testing decisions, safety conclusions, and risk acceptability determinations.

Consulting Services for QMSR Compliance

Beyond testing and analytical services, CROs can provide strategic consulting supporting manufacturers' QMSR compliance and biocompatibility evaluation.

QMSR Implementation Support

Gap analysis services. Assessing manufacturer quality systems against QMSR and ISO 13485:2016 requirements to identify compliance gaps.

Documentation development. Supporting quality manual updates, procedure revisions, and form modifications to align with QMSR requirements.

Training delivery. Providing QMSR training for manufacturer personnel at all levels, from executives to operational staff.

Mock inspections. Conducting process-based assessments using Compliance Program 7382.850 approach to prepare manufacturers for FDA inspection.

Biocompatibility Strategy Consulting

Biological evaluation planning. Helping manufacturers develop risk-based biological evaluation strategies under ISO 10993-1:2025.

Predicate analysis. Researching cleared or approved devices to support substantial equivalence arguments or identify biocompatibility precedents.

Testing strategy optimization. Determining the most efficient combination of chemical characterization, toxicological risk assessment, and biological testing to demonstrate safety.

Change control guidance. Advising on when material, process, or supplier changes require biocompatibility reassessment and what evaluation activities are needed.

Regulatory Submission Support

Biocompatibility section preparation. Writing biocompatibility sections for 510(k), PMA, or De Novo submissions that integrate chemical, toxicological, and biological data coherently.

FDA deficiency response. Preparing focused, scientifically sound responses to FDA questions about biocompatibility, chemical characterization, or toxicological risk assessment.

Pre-submission meeting support. Helping manufacturers prepare materials and strategy for FDA pre-submission meetings addressing biocompatibility or testing strategy questions.

Positioning Your CRO for QMSR Success

CROs that adapt to QMSR requirements and ISO 10993-1:2025's risk-based framework can differentiate themselves and provide greater value to manufacturer clients.

Building Competitive Advantages

Develop integrated service offerings. CROs providing both chemical characterization and biological testing, or testing plus toxicological interpretation, create more value than single-service providers.

Invest in toxicological expertise. Employing or partnering with qualified toxicologists enables CROs to offer interpretation and risk assessment services manufacturers desperately need.

Enhance quality system visibility. Obtain ISO 17025 accreditation, maintain robust quality systems, and communicate quality capabilities clearly to manufacturer clients operating under QMSR requirements.

Provide strategic consultation. Move beyond order-taking to strategic partnership, helping clients determine what testing is actually needed rather than just executing requested protocols.

Stay current on regulatory changes. Monitor FDA guidance, ISO standard updates, and industry trends to provide clients with current, relevant advice.

Communication and Documentation Excellence

Provide complete, traceable reports. Ensure test reports include all information manufacturers need for regulatory submissions and FDA inspection defense.

Explain limitations clearly. Document analytical detection limits, test system limitations, and any factors affecting result interpretation.

Support regulatory interactions. Be prepared to answer FDA questions about methods, results, or interpretations during manufacturer regulatory reviews.

Maintain responsive communication. Provide timely updates on project status, proactive notification of issues, and rapid response to client questions.

Common CRO Challenges Under the QMSR

Understanding typical challenges helps CROs prepare for evolving client expectations.

Challenge: Clients Don't Know What They Need

The issue: Manufacturers unfamiliar with ISO 10993-1:2025 request testing that may not be necessary or fail to request chemical characterization that is needed.

The solution: Provide consultative guidance helping clients understand risk-based biological evaluation requirements. Educate rather than simply executing orders that may not support clients' regulatory goals.

Challenge: Inadequate Test Article Information

The issue: Manufacturers provide test articles without sufficient information about materials, manufacturing processes, sterilization, or clinical use to design appropriate studies.

The solution: Establish clear test article requirements and intake processes. Refuse to proceed without adequate information rather than making assumptions that could invalidate results.

Challenge: Pressure for Fast Turnaround

The issue: Manufacturers with tight timelines pressure CROs to rush studies, potentially compromising quality or scientific rigor.

The solution: Set realistic timelines based on study complexity and maintain quality standards. Explain how rushing compromises defensibility during FDA review, ultimately costing more time than it saves.

Challenge: Limited Toxicological Expertise

The issue: CROs can generate analytical data but lack expertise to interpret toxicological significance or prepare risk assessments.

The solution: Partner with qualified toxicology consultants, hire toxicologists, or clearly communicate service limitations to clients so they can engage appropriate expertise separately.

The QMSR and ISO 10993-1:2025 fundamentally change what medical device manufacturers need from CROs. Organizations that adapt by offering integrated services, toxicological expertise, strategic consultation, and QMSR-aligned quality systems will thrive. Those that continue providing only routine testing without interpretation or strategic guidance will find themselves commoditized and undervalued.

CROs that position themselves as strategic partners—helping manufacturers navigate risk-based biological evaluation, optimize testing strategies, and maintain QMSR compliance—create sustainable competitive advantages and provide genuine value in an evolving regulatory landscape.

Expert Support for CROs Serving Medical Device Manufacturers

Successfully supporting medical device manufacturers under the QMSR requires more than testing capabilities—it demands toxicological expertise, regulatory knowledge, and strategic consulting abilities that most CROs don't possess internally.

At JL Tox Consulting, we partner with CROs to enhance their service offerings and provide the specialized expertise their manufacturer clients need for QMSR compliance and ISO 10993-1:2025 biological evaluation.

Our CRO partnership services include:

• Toxicological risk assessment services for CRO clients needing expert interpretation of chemical characterization data

• Biological evaluation report preparation integrating chemical, toxicological, and biological testing data

• Strategic consultation helping CROs guide manufacturer clients on risk-based biological evaluation strategies

• Scientific justification documentation for testing decisions and safety conclusions

• FDA deficiency response support when CRO clients receive biocompatibility or toxicology questions

• Training and knowledge transfer building CRO staff capabilities in toxicological risk assessment

We work collaboratively with CROs to enhance their value proposition while maintaining their client relationships. Our goal is to help CROs provide comprehensive, scientifically defensible services that support their manufacturer clients' regulatory success.

Contact JL Tox Consulting to discuss partnership opportunities:

Email: info@JLTox.com

Phone: (877) 899-6568